Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 880109

Controversy about pharmacological modulation of Nrf2 for cancer therapy


Milković, Lidija; Žarković, Neven; Saso, Luciano.
Controversy about pharmacological modulation of Nrf2 for cancer therapy // Redox Biology, 12 (2017), 727-732 doi:10.1016/j.redox.2017.04.013 (međunarodna recenzija, pregledni rad, znanstveni)


CROSBI ID: 880109 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Controversy about pharmacological modulation of Nrf2 for cancer therapy

Autori
Milković, Lidija ; Žarković, Neven ; Saso, Luciano.

Izvornik
Redox Biology (2213-2317) 12 (2017); 727-732

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
Cancer ; Nrf2 ; Oxidative stress ; Cancer therapy ; Growth regulation ; 4-hydroxynonenal

Sažetak
Conventional anticancer therapies such as radiotherapy and chemotherapies are associated with oxidative stress generating reactive oxygen species (ROS) and reactive aldehydes like 4-hydroxynonenal in cancer cells that govern them to die. The main mechanism activated due to exposure of the cell to these reactive species is the Nrf2-Keap1 pathway. Although Nrf2 was firstly perceived as a tumor suppressor that inhibits tumor initiation and cancer metastasis, more recent data reveal its role also as a pro-oncogenic factor. Discovery of the upregulation of Nrf2 in different types of cancer supports such undesirable pathophysiological roles of Nrf2. The upregulation of Nrf2 leads to activation of cytoprotective genes thus helping malignant cells to withstand high levels of ROS and to avoid apoptosis, eventually becoming resistant to conventional anticancer therapy. Therefore, new treatment strategies are needed for eradication of cancer and in this review, we will explore two opposing approaches for modulation of Nrf2 in cancer treatments.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekti:
098-0982464-2519 - Lipidi, slobodni radikali i njihovi glasnici u integrativnoj onkologiji (Žarković, Neven, MZOS ) ( CroRIS)

Ustanove:
Institut "Ruđer Bošković", Zagreb

Profili:

Avatar Url Lidija Milković (autor)

Avatar Url Neven Žarković (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Milković, Lidija; Žarković, Neven; Saso, Luciano.
Controversy about pharmacological modulation of Nrf2 for cancer therapy // Redox Biology, 12 (2017), 727-732 doi:10.1016/j.redox.2017.04.013 (međunarodna recenzija, pregledni rad, znanstveni)
Milković, L., Žarković, N. & Saso, L. (2017) Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biology, 12, 727-732 doi:10.1016/j.redox.2017.04.013.
@article{article, author = {Milkovi\'{c}, Lidija and \v{Z}arkovi\'{c}, Neven and Saso, Luciano.}, year = {2017}, pages = {727-732}, DOI = {10.1016/j.redox.2017.04.013}, keywords = {Cancer, Nrf2, Oxidative stress, Cancer therapy, Growth regulation, 4-hydroxynonenal}, journal = {Redox Biology}, doi = {10.1016/j.redox.2017.04.013}, volume = {12}, issn = {2213-2317}, title = {Controversy about pharmacological modulation of Nrf2 for cancer therapy}, keyword = {Cancer, Nrf2, Oxidative stress, Cancer therapy, Growth regulation, 4-hydroxynonenal} }
@article{article, author = {Milkovi\'{c}, Lidija and \v{Z}arkovi\'{c}, Neven and Saso, Luciano.}, year = {2017}, pages = {727-732}, DOI = {10.1016/j.redox.2017.04.013}, keywords = {Cancer, Nrf2, Oxidative stress, Cancer therapy, Growth regulation, 4-hydroxynonenal}, journal = {Redox Biology}, doi = {10.1016/j.redox.2017.04.013}, volume = {12}, issn = {2213-2317}, title = {Controversy about pharmacological modulation of Nrf2 for cancer therapy}, keyword = {Cancer, Nrf2, Oxidative stress, Cancer therapy, Growth regulation, 4-hydroxynonenal} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font